GlassScriptPhysician profile
Lindsay Hildreth
NPI 1740843234
$6,265.12
in general payments reported to CMS, 2019-2025
28 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,876 · 2022: $1,451 · 2023: $608 · 2024: $1,029 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,938.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $862.83 | 2021-2025 | |
| Alkermes, INC. | $664.45 | 2021-2025 | Aristada, Vivitrol, Lybalvi |
| Lundbeck LLC | $644.52 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $564.25 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $510.99 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $467.63 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $463.87 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $456.56 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $270.54 | 2021-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $173.53 | 2021-2025 | Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $155.24 | 2021-2025 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $121.37 | 2021 | |
| Bausch Health US, LLC | $111.99 | 2021-2024 | Aplenzin |
| Corium, LLC | $94.57 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $83.35 | 2024-2025 | Cobenfy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $83.08 | 2022-2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $75.48 | 2022-2024 | |
| Tris Pharma INC | $68.00 | 2024-2025 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $66.61 | 2021 | |
| Almatica Pharma LLC | $60.33 | 2021-2022 | |
| Novo Nordisk INC | $58.52 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $50.87 | 2023 | Qelbree |
| Eisai INC. | $47.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.71 | 2021 | |
| Biogen, INC. | $25.92 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $23.76 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $16.12 | 2022 | |
| Avanir Pharmaceuticals, INC. | $15.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Hildreth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.